ALNY Looks 55.6% Undervalued on GF Value™ Amid New Cardiovascular RNAi Data

gurufocus.com · 2026-08-30

On August 30, 2026, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) unveiled promising clinical results at the European Society of Cardiology Congress 2026, reinforc

Read the full story at gurufocus.com →